Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection

Abigail C. Geyer, Kali M. VanLangen, Andrew P. Jameson, Lisa E. Dumkow

Open source

DOI
10.1017/ash.2023.435
Published
2023
Container
Antimicrobial Stewardship & Healthcare Epidemiology
Publisher
Cambridge University Press (CUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1017/ash.2023.435,
  title = {Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection},
  author = {Abigail C. Geyer and Kali M. VanLangen and Andrew P. Jameson and Lisa E. Dumkow},
  year = {2023},
  journal = {Antimicrobial Stewardship \& Healthcare Epidemiology},
  doi = {10.1017/ash.2023.435},
  url = {https://doi.org/10.1017/ash.2023.435}
}

RIS

TY  - JOUR
TI  - Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection
AU  - Abigail C. Geyer
AU  - Kali M. VanLangen
AU  - Andrew P. Jameson
AU  - Lisa E. Dumkow
PY  - 2023
JO  - Antimicrobial Stewardship & Healthcare Epidemiology
DO  - 10.1017/ash.2023.435
UR  - https://doi.org/10.1017/ash.2023.435
ER  - 

APA

Geyer, A. C., VanLangen, K. M., Jameson, A. P., & Dumkow, L. E. (2023). Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection. Antimicrobial Stewardship & Healthcare Epidemiology. https://doi.org/10.1017/ash.2023.435

Source records